ABBV – AbbVie Stock: AbbVie Inc, a global biopharmaceutical company, focuses on developing and monetizing treatments within immunology, oncology, and neuroscience. For investors, predicting its stock trends is crucial to determine its potential as a future investment. This article reviews AbbVie’s stock analysis from 2025 to 2030, examining its financial achievements, market tendencies, and growth potential.
Founded in 2012 as a spin-off from Abbott Laboratories, AbbVie quickly became an industry titan. It is best known for Humira, a leading immunology treatment, and has also pioneered other treatments like Rinvoq and Skyrizi1. With a rich pipeline of products and the acquisition of Allergan, AbbVie has diversified its offerings across various therapy categories.
Table of Contents
AbbVie (ABBV) Company Overview
| Company Name | AbbVie (ABBV) Inc. |
| Founded | 2012 |
| Headquarters | North Chicago, Illinois, United States |
| Industry | Biopharmaceutical |
| Chairman | Richard A. Gonzalez |
| Stock Exchange Listing | NYSE, S&P |
| Official Website | abbvie |
AbbVie (ABBV) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Cap | $318.08B |
| ROE | — |
| P/E | 52.7 |
| P/B | 52.1 |
| Div. Yield | 3.64% |
| Book Value | — |
| EPS (TTM) | $1.00 |
| 52 Week High | $207.32 |
| 52 Week Low | $153.58 |
Also Read: NVIDIA Stock Price Prediction
AbbVie (ABBV) Financials
Income Statement
| (USD) | 2023 | Y/Y change |
|---|---|---|
| Revenue | 54.32B | -6.44% |
| Operating expense | 19.93B | 7.33% |
| Net income | 4.86B | -58.91% |
| Net profit margin | 8.95 | -56.11% |
| Earnings per share | 11.11 | -19.32% |
| EBITDA | 26.36B | -16.12% |
| Effective tax rate | 22.03% | — |
Balance Sheet
| (USD) | 2023 | Y/Y change |
|---|---|---|
| Cash and short-term investments | 12.82B | 38.87% |
| Total assets | 134.71B | -2.95% |
| Total liabilities | 124.31B | 2.30% |
| Total equity | 10.40B | — |
| Shares outstanding | 1.77B | — |
| Price to book | 30.39 | — |
| Return on assets | 8.07% | — |
| Return on capital | 14.44% | — |
Cash Flow
| (USD) | 2023 | Y/Y change |
|---|---|---|
| Net income | 4.86B | -58.91% |
| Cash from operations | 22.84B | -8.44% |
| Cash from investing | -2.01B | -222.47% |
| Cash from financing | -17.22B | 30.56% |
| Net change in cash | 3.61B | 762.94% |
| Free cash flow | 22.63B | -1.47% |
Also Read: JP Morgan Stock Price Forecast
ABBV- AbbVie Stock Price Forecast From 2025 to 2030
| Year | Target Price |
|---|---|
| AbbVie Stock Price Forecast​ 2025 | $220 |
| AbbVie Stock Price Forecast 2026 | $260 |
| AbbVie Stock Price Forecast 2027 | $280 |
| AbbVie Stock Price Forecast 2028 | $340 |
| AbbVie Stock Price Forecast 2029 | $310 |
| AbbVie Stock Price Forecast 2030 | $400 |
AbbVie (ABBV) Top Shareholders
| Investor | Ownership Percentage |
|---|---|
| Vanguard Fiduciary Trust Co. | 9.713% |
| BlackRock Advisors LLC | 5.988% |
| State Street Corp. | 4.474% |
| JPMorgan Investment Management, Inc. | 2.939% |
| Eaton Vance Management | 2.190% |
| Capital Research & Management Co. (International Investors) | 2.082% |
| Geode Capital Management LLC | 2.046% |
| Capital Research & Management Co. (Global Investors) | 1.879% |
| BlackRock Life Ltd. | 1.542% |
| Charles Schwab Investment Management, Inc. |
Also Read: Devon Energy Stock Price Forecast
AbbVie (ABBV) Competitors/Peer Companies
- UnitedHealth Group Incorporated
- Novo Nordisk A/S
- Johnson & Johnson
- Merck & Co Inc
- AstraZeneca PLC
- Thermo Fisher Scientific Inc
- Abbott Laboratories
- Novartis AG
- Intuitive Surgical Inc
- Danaher Corp
Also Read: AMZN – Amazon Stock Price Forecast
To connect with us, click on any of the given social media buttons.
FAQs
-
What is AbbVie (ABBV) Stock Price Prediction for 2025?
220 USD.
-
What is AbbVie (ABBV) Stock Price Prediction for 2026?
260 USD.
-
What is AbbVie (ABBV) Stock Price Prediction for 2027?
280 USD.
-
What is AbbVie (ABBV) Stock Price Prediction for 2029?
310 USD.
-
What is AbbVie (ABBV) Stock Price Prediction for 2030?
400 USD.
We have more than 7 years of experience in the stock market and analysis, and we are dedicated to delivering accurate, real-time market updates and insightful analysis. With a sharp eye on the Indian and global stock markets, we simplify complex financial data and trends to help investors make informed decisions.
Disclaimer: All the information provided in this article is for educational purposes only. We are not a SEBI registered firm. DateUpdateGo always advises seeking guidance from a certified financial advisor before making any investment-related decisions.
